Up­dat­ed: No­var­tis re­jigs late-stage plans for Cosen­tyx, next-gen CAR-T, TIG­IT an­ti­body and more

No­var­tis has cleaned up its Phase III slate, shelv­ing late-stage plans for pro­grams across in­flam­ma­to­ry dis­eases and can­cer, the Swiss phar­ma gi­ant

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.